AbbVie Inc. (ABBV)
Pharma companies less concerned after hearing from US on negotiated prices for Medicare
Four pharmaceutical companies involved in the first U.S. negotiations over prices for the Medicare program said they do not expect a significant impact on their businesses after seeing confidential suggested prices from the government for their drugs that will take effect in 2026.
AbbVie: Growth Is Still A Better Choice
On July 25, AbbVie released its Q2 2024 financial results, which surprised me with surging sales of its immunology and neuroscience franchises. So, Rinvoq's sales amounted to $1.43 billion for the three months ended June 30, 2024, an increase of 55.8% year-on-year. On the other hand, sales of Elahere, a targeted anticancer drug, amounted to $128 million in the second quarter of 2024, increasing by 65.4% year-on-year.
3 High-Yield Dividend Stocks That Are Looking Super Hot
High-yield dividend stocks are attractive investment options as they provide regular payouts regardless of market performance. Understanding dividend yield, which is a ratio showing annual dividend income per dollar invested, is crucial for comparing investments.
AbbVie: Q2 Earnings Validate Bullish Case
AbbVie's recent Q2 earnings release was robust, validating my initial bullish thesis, which has aged well as the stock has outperformed the broader market since mid-April. The Q2 earnings release strengthened my bullish stance due to the robust performance across all business lines, solid operating leverage, and immense momentum in AbbVie's flagship products. According to my valuation analysis, ABBV stock is still around 35% undervalued.
AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
On Thursday, AbbVie Inc. ABBV reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57.
Why AbbVie Stock Was Cruising Higher on Thursday
The pharmaceutical sector mainstay posted a mixed second quarter. It topped analyst expectations for revenue and missed those for profitability, but investors were more focused on the future.
AbbVie Stock Hits Record High on Demand for Non-Humira Portfolio
AbbVie (ABBV) shares traded at an all-time high Thursday as the biopharmaceutical firm posted better-than-expected revenue and boosted its guidance as demand for its other drugs offset a decline in Humira sales.
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AbbVie Stock News: Why ABBV Is the Top Trending Ticker Today
AbbVie (NYSE: ABBV ) stock is the top trending ticker on Yahoo Finance on Thursday as investors are pumped up about news from the pharmaceutical company's latest earnings report. AbbVie started its earnings report for Q2 with adjusted EPS of $2.65.
Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
AbbVie (ABBV) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.91 per share a year ago.
